Skip to main content
Back to timeline
AsimovSource publication:

Asimov and Emergent sign two cell-line campaigns: CHO Edge to build high-titer research banks for two Ebola antibodies

Synopsis

Asimov and Emergent BioSolutions announced a cell-line development partnership covering two full campaigns, running from vector design and synthesis through production and shipment of a high-titer research cell bank, for two monoclonal antibodies targeting Ebola. Emergent aims to obtain high-titer cell lines using Asimov's CHO Edge System, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, Asimov's AI-driven genetic design software. The work sits at the cell-line development stage, and the companies describe an intent to accelerate candidate antibody development without reporting titers or antibody results.

Source-provided article image: Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
Asimov

Interpretation

The two companies set the partnership's scope at two full cell-line development campaigns, each starting from vector design and synthesis and ending with production and shipment of a high-titer research cell bank, for two monoclonal antibodies targeting Ebola. Emergent has long developed, manufactured and delivered medical countermeasures against biological threats including anthrax, smallpox, mpox, botulism and Ebola, and now hands cell-line construction for two of its Ebola antibodies to an external platform. The partnership was announced in a joint press release that names the start and end steps of both campaigns and the two antibodies' target, while disclosing no titers, timelines or financial terms.

The construction work is carried by Asimov's CHO Edge System, which puts four components together: a GS knock-out CHO host, a hyperactive transposase, a genetic parts library, and AI-driven genetic design software called Kernel. Emergent's stated aim is to obtain high-titer cell lines with this system; the release states that aim and does not describe any earlier cell-line development path. Asimov describes CHO Edge as a combined approach aimed at high-titer cell lines, with Kernel handling genetic design; the release reports no measured result for the system on Ebola antibodies.

Perspective

The report is limited to what the joint press release states: two cell-line development campaigns, two monoclonal antibodies targeting Ebola, and the division of steps from vector design and synthesis to production and shipment of a high-titer research cell bank. It is written for researchers and engineers following biodefense countermeasures and cell-line engineering. The release proposes no next experiment or delivery date.

The release frames accelerating candidate antibody development and strengthening preparedness as the partnership's aims and potential benefits, and its forward-looking statement cautions that actual results may differ; whether the cell lines reach high titers and when the campaigns finish are not given.